esophageal squamous cell carcinoma (escc)

ZSH-2208 is a retinoic acid A analogue that inhibits tumour cell proliferation and survival through RARγ-TNFAIP3 and retinoid receptors.

SL-3-19 is a tubulin ligand that exhibits antitumor activity against esophageal squamous cell carcinoma (ESCC) both in vitro and in vivo. It functions by inhibiting microtubule assembly, inducing G2/M phase cell cycle arrest and apoptosis, and disrupting tumor vasculature. SL-3-19 is more potent than SL-1-73 and can be utilized in research involving ESCC and similar tumors.

SL-1-73 is a tubulin ligand. It exhibits antitumor activity against esophageal squamous cell carcinoma (ESCC) both in vitro and in vivo by inhibiting tubulin assembly, inducing G2/M phase cell cycle arrest and apoptosis, and disrupting tumor vasculature. SL-1-73 is useful for research in ESCC and other tumors.

RSK4-IN-2 (compound 16o) is a potent orally active RSK4 inhibitor with an IC50 of 17 nM. It hinders the growth and invasion of esophageal squamous cell carcinoma (ESCC) cells by inhibiting the phosphorylation of RSK4 downstream targets. Additionally, RSK4-IN-2 impedes tumor growth and metastasis in a mouse model of ESCC, making it valuable for ESCC research.

TFAP2β modulator-1 (compound A6) is a potent TFAP2β modulator that enhances the aggregation of TFAP2β by inducing conformational changes in its intrinsically disordered regions. The compound induces apoptosis and exhibits antitumor activity in esophageal squamous cell carcinoma (ESCC) cells, mouse models, and organoids. TFAP2β modulator-1 is applicable for research related to ESCC.

LD-110 is a potent PROTAC degrader targeting LSD1 with a DC50 of 0.44 μM. It promotes LSD1 degradation via a ubiquitin-proteasome-dependent mechanism and enhances H3K4 dimethylation levels. By inducing apoptosis, LD-110 inhibits the growth and survival of various esophageal squamous cell carcinoma (ESCC) cell lines. It is applicable for research on esophageal squamous cell carcinoma.

PFK-015 (PFK15) is an effective inhibitor of PFKFB3 (IC50: 110 nM) and inhibits PFKFB3 activity in Y cells (IC50: 20 nM).

Afatinib (BIBW 2992) oxalate is an irreversible, orally active bispecific inhibitor of the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM for EGFRwt, 0.4 nM for EGFRL858R, 10 nM for EGFRL858R/T790M, and 14 nM for HER2. Afatinib oxalate can be used to study esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer.

(R)-Afatinib ((R)-BIBW 2992), an isomer of Afatinib, is a potent, orally administered, irreversible inhibitor targeting the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM for EGFR wt, 0.4 nM for EGFR L858R, 10 nM for EGFR L858R/T790M, and 14 nM for HER2, holding potential for research into esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer [1].

ERK-IN-6 (compound 6g) is a potent anti-proliferative agent against esophageal squamous cell carcinoma (ESCC), inducing apoptosis via the ERK pathway, with potential applications in ESCC research [1].

Xerophilusin B, isolated from Isodon xerophilus as an anticancer agent, demonstrates antiproliferative effects on esophageal squamous cell carcinoma (ESCC) cell lines. It induces G2/M cell cycle arrest and mediates apoptosis [1].